Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ABCL635

Other · developed by AbCellera Biologics

Phase 1/2 Most advanced trial
ABCL Developer
1 Registered trials

What is ABCL635?

ABCL635 is an investigational drug studied in Vasomotor Symptoms Associated With Menopause, Healthy Volunteers.

At a glance

Drug type
Other
Therapy area
Endocrine
Developer
AbCellera Biologics Inc. (ABCL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07118891 Phase 1/2 Vasomotor Symptoms Associated With Menopause Active not recruiting ABCL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersVasomotor Symptoms Associated With Menopause

More from AbCellera Biologics

ABCL575 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABCL page.

Follow ABCL, the company behind ABCL635

See ABCL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABCL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.